Buijsen et al. investigated various pre-treatment biomarkers, including the plasma CRP level, as predictive factors for tumor response after nRCT, but did not detect a significant relationship between the pre-treatment CRP level and complete or good response after nRCT [25]. This evidence concerns the gene CRP and neoplasm.